Tobacco vs. Nicotine
This is the cleanest example of the orchestral principle, and the most commercially important. Tobacco is not nicotine. They overlap, but the addiction profile, withdrawal severity, and even the receptor pharmacology differ significantly.
Module 5a treated tobacco-smoking and pure-nicotine use as roughly equivalent for the purposes of explaining receptor mechanics. They are not equivalent as drugs.
Tobacco smoke contains over 7,000 distinct chemicals (Talhout et al., 2011). Several are pharmacologically active in ways that matter for addiction:
What's Actually in Tobacco
- Binds α4β2 nAChRs as described in Module 5a
- Half-life ~2 hours
- Acutely raises dopamine in NAc
Tobacco smoke contains harman and norharman, β-carboline alkaloids that inhibit MAO in the brain. Specifically, Fowler et al. (1996) demonstrated MAO-B inhibition via PET imaging; inhibition of MAO-A and broader monoamine oxidase activity has been shown by Lewis et al. (2007).
- Brain MAO-B activity is reduced ~30–40% in smokers vs. non-smokers — PET imaging data (Fowler et al., 1996)
- MAO is the enzyme that breaks down dopamine, serotonin, and norepinephrine. Inhibit it → all three linger longer
- Key point: the dopamine surge from tobacco is bigger and longer-lasting than from pure nicotine, because tobacco simultaneously blocks dopamine breakdown
- Reacts with biogenic amines to form salsolinol-like compounds with dopamine-releasing effects (DeNoble & Mele, 2006)
- Increases nicotine's reinforcing strength in animal models
- Weak agonists at nAChRs in their own right
- Modulate nicotine's binding kinetics
- Contribute to the overall cholinergic "feel" beyond what pure nicotine produces
- Engineered specifically to increase palatability, accelerate absorption, and increase consumption (Stepanov et al., 2012)
- Menthol opens cooling receptors (TRPM8), suppresses cough reflex → deeper inhalation → more drug delivered per puff
Why This Matters for Addiction
| Variable | Tobacco smoke | Vaping (nicotine) | Pure NRT (patch/gum) |
|---|---|---|---|
| Onset speed | Fast (seconds via lung) | Fast–moderate | Slow (minutes–hours) |
| Dopamine surge size | Large (nicotine + MAOI) | Moderate (no MAOIs) | Small |
| MAO inhibition | ~30–40% reduction | None | None |
| Dependence strength | Very high (~67% lifetime) | High (better than smoking, harder than NRT) | Moderate — viable tapering tool |
This is why nicotine replacement therapy works at all — the drug being replaced (tobacco smoke) is much more addictive than the drug replacing it (medicinal nicotine), so the user can taper from a strong reinforcer to a weak one. If smoking and nicotine gum were truly the same drug, NRT would simply maintain the addiction. It doesn't.
It's also why vaping is harder to quit than NRT but easier than smoking. Vaping delivers nicotine faster than NRT (closer to smoking kinetics) but lacks the MAOIs and combustion byproducts of tobacco. Mechanistically, it sits between the two.
Implication
Lifetime dependence on tobacco is ~67% of users. If pure nicotine carried the same dependence risk, NRT would not be a viable treatment. The full plant — with its MAOIs, acetaldehyde, secondary alkaloids, and combustion-engineered absorption — is significantly more addictive than its main alkaloid alone.